Expectations and Limitations of Artificial Intelligence in Blood Cancer Diagnosis [0.03%]
人工智能在血液癌症诊断中的期望和局限性分析
Charlotte Syrykh,Sarah Bertoli,Jean-Marc Alliot et al.
Charlotte Syrykh et al.
In this commentary, we open the debate on what can be expected from artificial intelligence (AI) in the diagnosis of hematologic cancers. We discuss the key factors that make AI solutions robust, trustworthy, and, above all, generalizable, ...
No BCMA? No Problem: A CD70-Targeting CAR-NK Cell Shows Promise in High-risk Myeloma [0.03%]
无BCMA？没问题！针对CD70的CAR-NK细胞在高危多发性骨髓瘤中显示出希望
Don M Benson Jr,Michael A Caligiuri
Don M Benson Jr
Despite recent advances, multiple myeloma remains essentially incurable for most patients, particularly those with high-risk cytogenetics and those whose disease relapses after BCMA-targeting therapies. A novel CD27 CAR_sIL15 NK cell target...
Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome [0.03%]
免疫效应细胞相关的噬血细胞综合征的临床和细胞因子特征
Hrishikesh K Srinagesh,Anne Marijn Kramer,John H Baird et al.
Hrishikesh K Srinagesh et al.
CAR-T cells targeting CD22 (CAR22) are associated with IEC-HS. However, CAR22-related IEC-HS has not been detailed in LBCL or adults with B-ALL. Here, we describe the manifestations of IEC-HS in patients with LBCL and B-ALL. IEC-HS was comm...
Dimitrios Papaioannou,Iannis Aifantis
Dimitrios Papaioannou
Intratumoral heterogeneity and subclonal diversity, characterized by the coexistence of genetically and functionally distinct leukemic cell populations within a single patient, have long been recognized as major contributors to chemotherapy...
Overcoming BTK Inhibitor Resistance in Chronic Lymphocytic Leukemia by Targeting PKCβ [0.03%]
通过靶向PKCβ克服慢性淋巴细胞白血病中BTK抑制剂的耐药性
Billy Michael Chelliah Jebaraj,Stephan Stilgenbauer
Billy Michael Chelliah Jebaraj
Resistance of chronic lymphocytic leukemia to BTK inhibitors poses a major clinical challenge; however, there is potential to overcome this obstacle by targeting the downstream protein kinase PKCβ using the novel inhibitor MS-553. By inhib...
Longitudinal profiling of tumor and immune compartments uncovers patterns of dysregulation and associations with response in multiple myeloma [0.03%]
纵向分析肿瘤和免疫组分发现多发性骨髓瘤中的失调模式及其与反应的关联
Denis J Ohlstrom,William C Pilcher,Marina E Michaud et al.
Denis J Ohlstrom et al.
Multiple myeloma (MM) is a malignancy of clonally expanded plasma cells shaped by complex interactions with the immune microenvironment. To investigate immune correlates of treatment response and disease progression, we conducted multi-omic...
Molecular Plasticity Results in Oncofetal Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia [0.03%]
分子可塑性导致儿童粒单核细胞白血病中的癌胎生物重编程及治疗弱点
Mark Hartmann,Maximilian Schönung,Jovana Rajak et al.
Mark Hartmann et al.
Persistent fetal gene expression in childhood neoplasms is usually explained by a maturation block originating in the prenatal phase. In contrast, reactivation of fetal genes in adult malignancies is considered a consequence of oncofetal re...
Human TET2-mutant clonal hematopoiesis expansion is driven by distinct inflammatory signaling responses in stem cells versus myeloid progeny [0.03%]
人TET2突变克隆型血液病的扩增是由造血干细胞和髓系后代炎症信号反应驱动的不同的过程
Hector Huerga Encabo,Giuseppe D&#x;Agostino,Katherine Sturgess et al.
Hector Huerga Encabo et al.
Clonal hematopoiesis (CH) increases with age and is associated with severe outcome in the course of infections or tumor development. Understanding the environmental conditions that favor mutant clones and the CH-immune system response to su...
Beyond Expansion: Tumor Debulking as Key to Improving CAR T-Cell Potential in Lymphoma [0.03%]
CAR-T细胞治疗淋巴瘤除了扩增作用还有啥？一篇Nature子刊揭示新的机制
Philipp M Altrock
Philipp M Altrock
In this issue of Blood Cancer Discovery, Pomeroy and colleagues explore a population pharmacokinetic/pharmacodynamic model of axicabtagene ciloleucel in large B-cell lymphoma, quantifying how tumor debulking before chimeric antigen receptor...